Regeneron Pharmaceuticals

This trial tests three experimental antibodies—REGN9933, REGN7508, and REGN9533—in people with end-stage kidney disease who are on hemodialysis. The goal is to see if these antibodies can safely reduce blood clot risk during dialysis, potentially offering an alternative to standa…

This trial is testing an experimental drug called REGN17235 in people with two related blood conditions: clonal cytopenia of undetermined significance (CCUS) and low-risk myelodysplastic syndrome (MDS), both linked to a specific genetic change called an SF3B1 mutation. The main g…

This study tests two experimental drugs, REGN7508 and REGN9933, to see if they can prevent blood clots in people who have a peripherally inserted central catheter (PICC). People with PICCs are at higher risk for venous thromboembolism (VTE), which can be serious. The trial compar…

This study tests an experimental drug, olatorepatide, which mimics natural hormones to help with weight loss. It involves 360 adults with overweight or obesity (but not diabetes) who receive different doses or a placebo. Researchers will check safety, side effects, how the drug w…

This study tests an experimental drug called REGN22530 in people with primary open angle glaucoma or ocular hypertension. The drug is designed to block a protein in the eye that causes fluid buildup and high pressure. Researchers are checking for side effects, how the drug moves …

This study tests an experimental drug called ALN-CIDEB in 150 adults with MASH, a serious liver disease involving fat buildup and scarring. The goal is to see if the drug can reduce liver fat, injury, and scarring compared to a placebo. Participants will receive either the drug o…

This large phase 3 trial tests an experimental drug, REGN7508, against the standard blood thinner apixaban for preventing strokes in people with atrial fibrillation (an irregular heartbeat). The study will enroll over 15,000 participants to compare how well each drug prevents str…

This study tests whether adding dupilumab to standard COPD treatment can prevent another flare-up or hospital stay within 90 days. About 754 adults who were recently hospitalized for a COPD exacerbation will receive either dupilumab or a placebo. The goal is to see if the drug re…

This study tests two immunotherapy drugs, fianlimab and cemiplimab, in children and young adults with recurrent high-grade glioma or ependymoma. The goal is to see if the combination is safe and can shrink tumors or slow their growth. Participants will receive the drugs before an…

This Phase 3 trial tests garetosmab, an antibody that blocks activin A, in 18 children and teens with fibrodysplasia ossificans progressiva (FOP), a rare disease where muscle and tissue turn into bone. The study will check safety, side effects, and whether the drug reduces new ab…

This study aims to identify and describe people with allergic conjunctivitis (eye allergies) caused by cats or birch tree pollen, with or without accompanying allergic rhinitis (hay fever). Researchers will collect information and perform allergy tests to see who qualifies for fu…

This study is the first time REGN22044 is given to humans. It will enroll 64 healthy adults to check for side effects, measure drug levels in the blood, and see if the body makes antibodies against it. The goal is to gather safety and dosing information, not to treat any disease.